| Literature DB >> 28326332 |
Daniela Marchetti1, Danilo Carrozzino2, Federica Fraticelli3, Mario Fulcheri1, Ester Vitacolonna3.
Abstract
Background and Objective. Diagnosis of Gestational Diabetes Mellitus (GDM) could significantly increase the likelihood of health problems concerning both potential risks for the mother, fetus, and child's development and negative effects on maternal mental health above all in terms of a diminished Quality of Life (QoL). The current systematic review study is aimed at further contributing to an advancement of knowledge about the clinical link between GDM and QoL. Methods. According to PRISMA guidelines, PubMed, Web of Science, Scopus, and Cochrane databases were searched for studies aimed at evaluating and/or improving levels of QoL in women diagnosed with GDM. Results. Fifteen research studies were identified and qualitatively analyzed by summarizing results according to the following two topics: GDM and QoL and interventions on QoL in patients with GDM. Studies showed that, in women with GDM, QoL is significantly worse in both the short term and long term. However, improvements on QoL can be achieved through different intervention programs by enhancing positive diabetes-related self-management behaviors. Conclusion. Future studies are strongly recommended to further examine the impact of integrative programs, including telemedicine and educational interventions, on QoL of GDM patients by promoting their illness acceptance and healthy lifestyle behaviors.Entities:
Mesh:
Year: 2017 PMID: 28326332 PMCID: PMC5343261 DOI: 10.1155/2017/7058082
Source DB: PubMed Journal: J Diabetes Res Impact factor: 4.011
Figure 1Flowchart of the systematic search.
Characteristics of included studies assessing the impact of GDM on Quality of Life.
| Study | Country/setting/year | Study design | Aim |
| Measure of Quality of Life |
|---|---|---|---|---|---|
| Bień et al. [ | Poland | Observational study without control group | To assess the factors affecting QoL (and illness acceptance) in pregnant women diagnosed with GDM. | 114 pregnant women with GDM | WHOQOL-BREF |
|
| |||||
| Danyliv et al. [ | Ireland | Observational | To compare QoL between GDM and NGT women 2 to 5 years after pregnancy. To explore participants characteristics which may influence their QoL. | 234 women diagnosed with GDM during pregnancy | Visual Analog Scale of the EQ-5D-3L |
|
| |||||
| Kopec et al. [ | Poland | Observational | To assess, among other objectives, factors affecting the QoL of pregnant women with GDM. | 205 pregnant women diagnosed with GDM | SF-8 |
|
| |||||
| Trutnovsky et al. [ | Austria | Observational | To evaluate, among other outcomes, QoL of women treated for GDM. | 45 pregnant women affected by GDM, divided based on type of treatment: | WHOQOL-BREF |
|
| |||||
| Lapolla et al. [ | Italy | Observational | To evaluate QoL, wishes, and needs of Italian and immigrant women diagnosed with GDM. | 286 pregnant women affected by GDM, divided into two groups: | QoL is only indirectly evaluated with questions covering feelings and concerns related to the diagnosis of GDM and its treatment |
|
| |||||
| Dalfrà et al. [ | Italy | Observational study with control group | To examine the impact of diabetes on QoL among pregnant women with diabetes (GDM and T1DM) compared with pregnant women with a normal glucose tolerance. | 245 women divided into three groups: | SF-36 |
|
| |||||
| Halkoaho et al. [ | Finland | Observational | To evaluate the effects of GDM on women's QoL after delivery. | 77 women diagnosed with GDM during pregnancy | 15D HRQoL |
|
| |||||
| Mautner et al. [ | Austria | Observational | To explore QoL (and the incidence of depressive symptoms) in women during pregnancy and after delivery, comparing women with GDM, hypertensive disorders, and risk for preterm delivery with a control group characterized by uncomplicated pregnancy. | 90 pregnant women, divided into four groups: | WHOQOL-BREF |
|
| |||||
| Kim et al. [ | California, USA | Observational | To investigate the influence of GDM (and PIH) on maternal health status, testing the hypothesis that, among others, women with GDM would have a great likelihood to report declines in health status than women without GDM, with at least a partial mediation by cesarean birth or preterm delivery. | 1445 pregnant women divided into three groups: | Physical functioning scale, vitality scale, and self-rated health item of the SF-36 |
|
| |||||
| Rumbold and Crowther [ | South Australia | Observational | To survey pregnant women on their experience of being screened for GDM, testing the hypothesis that women with a GDM diagnosis would experience a reduction in QoL (perception of the pregnancy, their health, and that of their baby) compared with women with a negative screening result. | 145 pregnant women divided into two groups | SF-36 |
GDM: Gestational Diabetes Mellitus; NGT: normal glucose tolerance; OGTT: oral glucose tolerance test; QoL: Quality of Life; PIH: pregnancy-induced hypertension; T1DM: type 1 diabetes mellitus; EQ-5D-3L: 3-level version of the EuroQol 5-Dimension; 15D HRQoL: 15-Dimensional Health-Related Quality of Life; SF-36: 36-Item Short-Form Health Survey; SF-8: 8-Item Short-Form Health Survey; WHOQOL-BREF: World Health Organization Quality of Life-BREF.
Characteristics of included studies assessing the impact of treatments on Quality of Life among GDM pregnant women.
| Study | Country/setting/year | Study design | Aim |
| Measure of Quality of Life |
|---|---|---|---|---|---|
| Latif et al. [ | England | Quasi-experimental study | To examine QoL (and treatment satisfaction) of women affected by GDM receiving metformin alone, insulin alone, or a combination of both treatments. | 128 women diagnosed with GDM during pregnancy | ADDQoL |
|
| |||||
| Petkova et al. [ | Bulgaria | Quasi-experimental study | To investigate the effectiveness of an educational program for pregnant women with GDM on their QoL (and other outcomes). | 30 pregnant women affected by GDM assigned to one of two conditions: | Five items measuring QoL |
|
| |||||
| Dalfrà et al. [ | Italy | Quasi-experimental study | To assess the effect of a telemedicine intervention on QoL (and other outcomes) among pregnant women with diabetes (GDM and T1DM). | 235 pregnant women divided into two groups: | SF-36 |
|
| |||||
| Elnour et al. [ | United Arab Emirates | Experimental | To evaluate the effect of a pharmaceutical care intervention programme for women with GDM on QoL (and other outcomes) both during pregnancy and after delivery. | 180 pregnant women diagnosed with GDM | SF-36 |
|
| |||||
| Crowther et al. [ | New South Wales; Queensland; South Australia; England; Wales | Experimental | To examine the effect of an intervention (including dietary advice, blood glucose monitoring, and insulin therapy) for women with GDM on QoL (and other primary and secondary outcomes). | 1000 pregnant women with GDM, randomly assigned to one of two conditions: | SF-36 |
GDM: Gestational Diabetes Mellitus; QoL: Quality of Life; T1DM: type 1 diabetes mellitus; ADDQoL: Audit of Diabetes-Dependent Quality of Life; SF-36: 36-Item Short-Form Health Survey.
Diagnostic criteria for GDM of included studies.
| Study | Time and methods of diagnosis | Diagnostic criteria |
|---|---|---|
| Bień et al. [ | Diabetes first diagnosed during pregnancy, in accordance with the current guidelines of the Polish Diabetology Society: for pregnant women with risk factors, the 75 g OGTT is required. If glycemia is normal, the test should be readministered at 24–28 weeks of pregnancy or when first symptoms indicative of diabetes are observed. For women without risk factors, the 75 g OGTT is administered at 24–28 weeks of pregnancy | 75-g OGTT: |
|
| ||
| Danyliv et al. [ | Pregnant women were offered screening at 24–28 weeks' gestation using a 75 g OGTT | 75 g OGTT in accordance with the IADPSG criteria |
|
| ||
| Kopec et al. [ | GDM was diagnosed by a two-step approach. The oral GCT administered between 24 and 28 weeks of pregnancy. Women with 1 h PG level >180 mg/dl (10.0 mmol/l) in the OGCT were classified as having GDM. Women with PG levels between 140 mg/dl (7.8 mmol/l) and 180 mg/dl (10.0 mmol/l) were referred for a diagnostic 75 g OGTT | Two-step approach: |
|
| ||
| Latif et al. [ | GDM was diagnosed at 28 weeks of pregnancy | A 2 h 75 g OGTT according to the WHO diagnostic criteria |
|
| ||
| Trutnovsky et al. [ | Diagnosed GDM based on the results of an elevated 75 g OGTT | Diagnostic criteria not fully specified |
|
| ||
| Lapolla et al. [ | GDM was diagnosed according to Carpenter and Coustan's criteria | Carpenter and Coustan's criteria |
|
| ||
| Dalfrà et al. [ | Screening for GDM was done with a GCT between the 24th and 28th weeks of gestation, and the diagnosis was confirmed with a 100 g OGTT, interpreting the results according to the Recommendations of the 4th International Workshop Conference on GDM | Carpenter and Coustan's criteria |
|
| ||
| Petkova et al. [ | Women, suspected to have GDM, were subjected to 2 h 75 g GCT. Those with sugar level around 140 mg/dl (7.8 mmol/L) or above were requested for OGTT recommended by WHO | Two-step approach: |
|
| ||
| Halkoaho et al. [ | The diagnosis of GDM is based on a 2 h glucose tolerance test generally administered during the 24th–28th weeks of pregnancy to women with GDM risk factors | Diagnostic criteria not fully specified |
|
| ||
| Mautner et al. [ | The group “gestational diabetes” included women diagnosed with a pathological oral glucose tolerance test requiring insulin therapy at the end of the second and the beginning of the third trimester. The diagnosis of GDM is based on a pathological OGTT | Diagnostic criteria not fully specified |
|
| ||
| Dalfrà et al. [ | Screening for GDM was done with a GCT between the 24th and 28th weeks of gestation, and the diagnosis was confirmed with a 100 OGTT | Carpenter and Coustan's criteria |
|
| ||
| Elnour et al. [ | Women within the first 20 weeks of gestation confirmed diagnosis of GDM | Diagnostic criteria not specified |
|
| ||
| Kim et al. [ | GDM was diagnosed according to Carpenter and Coustan's criteria between 24–28 weeks of gestation | Carpenter and Coustan's criteria |
|
| ||
| Crowther et al. [ | Pregnancy between 16 and 30 weeks' gestation with one or more risk factors for gestational diabetes on selective screening or a positive 50 g GCT and a 75 g OGTT at 24 to 34 weeks' gestation in accordance with the WHO diagnostic criteria | Two-step or one-step approach: |
|
| ||
| Rumbold and Crowther [ | Universal antenatal screening for GDM by either a random blood sample or a 50 g GCT at 24 to 28 weeks' gestation. Women who screen positive are offered a diagnostic 75 g OGTT | Two-step approach: |
GCT: glucose challenge test; GDM: Gestational Diabetes Mellitus; IADPSG: International Association of Diabetes and Pregnancy Study Groups; OGTT: oral glucose tolerance test; WHO: World Health Organization.